GlobeNewswire by notified

Amii’s Upper Bound conference invites all to experience the future of AI

Share

The third installment of Upper Bound delivers world-class research, prominent speakers, diverse sessions and unlimited possibilities for all

EDMONTON, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Amii (Alberta Machine Intelligence Institute) is thrilled to welcome the global AI community to Edmonton, Alberta, Canada for Upper Bound, May 21-24. Billed as “not your average AI conference”, Upper Bound invites thousands of AI researchers, business leaders, students, enthusiasts and the AI curious to attend the multi-day event for AI-focused learning, discussion, debate and collaboration with some of the world’s top thinkers, visionaries, and business innovators.

This year, Upper Bound features prominent speakers who are at the global forefront of AI research and applications. Among the distinguished speakers are:

  • Richard S. Sutton, AI visionary and Amii Chief Scientific Advisor, often named the forefather of reinforcement learning.
  • James Cameron, NVIDIA
  • Anna Baird, Google
  • Doina Precup, DeepMind
  • Finbarr Timbers, MidJourney

“In today’s rapidly evolving landscape, the imperative to embrace AI is more pronounced than ever. The transformative power of AI is reshaping industries, creating new possibilities and driving unprecedented growth. Now is the time for us to dive deep into the realm of AI, exploring its boundless potential and leveraging its capabilities for the greater good,” said Cam Linke, CEO of Amii. “Upper Bound is a unique platform for the global AI community to convene, collaborate, and seize the opportunity to lead the charge in AI innovation. This is an invitation for all to explore the limitless possibilities of AI, embark on this collective journey and chart a course towards a brighter and optimistic AI-driven future.”

This year Upper Bound will delve into a diverse array of program themes that are pivotal in today's AI-driven world. Attendees can expect deep dives into themes crucial for shaping the future of AI across various industries such as the Business of AI, AI in Agriculture, AI in Law, AI in Games, AI & Government Services, and more.

Complete overview of Upper Bound 2024 program themes

Designed with a diverse audience in mind, Upper Bound includes technical and non-technical sessions, community events, demos, networking socials and the biggest party in town – the official Upper Bound Party.

Last year more than 3000 attendees from 22 countries attended Upper Bound with Amii awarding over 800 Talent Bursaries to recipients from all over the world and 81% of recipients self-identifying as a marginalized group in STEM.

Choose your Upper Bound experience: $500 4-day all-access conference pass

$25 Upper Bound party only

Upper Bound is proudly presented by Amii. A global leader in AI research and industry solutions, Amii is one of the three national AI Institutes and centres of excellence under the Pan-Canadian AI Strategy. Learn more at amii.ca.

For media inquiries, media passes and interviews contact:
Lynda Vang, Communications Specialist
lynda.vang@amii.ca

About Amii
One of Canada’s three centres of AI excellence as part of the Pan-Canadian AI Strategy, Amii is an Alberta-based non-profit institute that supports world-leading research in artificial intelligence and machine learning and translates scientific advancement into industry adoption. Amii grows AI capacity by advancing leading-edge research, delivering exceptional training offerings, and providing business advice to build in-house AI capabilities. For more information, visit: amii.ca.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ce037c32-9ecb-4627-8e5b-59d23744cb76

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye